Effect of co-administration of HMG-CoA Reductase Inhibitor on the endothelial dysfunction after continuous treatment of nitroglycerin in Japanese volunteers with aldehyde dehydrogenase2 Glu487Lys genotypes: randomized crossover trial

Effect of co-administration of HMG-CoA Reductase Inhibitor on the endothelial dysfunction after continuous treatment of nitroglycerin in Japanese volunteers with aldehyde dehydrogenase2 Glu487Lys genotypes: randomized crossover trial - Effect of HMG-CoA Reductase Inhibitor on the endothelial dysfunction in Japanese volunteers with ALDH2 mutation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013382

Enrollment

Registered

2014-03-11

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

angina pectoris

Interventions

nitroglycerin 25 mg/day is transdermally administered for 7 days nitroglycerin 25 mg/day and atorvastatin 20 mg/day are administered for 7 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Japanese healthy volunteers who are older than 20 and younger than 40

Exclusion criteria

Exclusion criteria: 1. History of cardiovascular disease 2. Severe hepatic dysfunction 3. Severe renal dysfunction 4. Woman who is pregnant or possibly be pregnant 5. History of severe allergy or allergic reaction to the drugs which are used in the present study 6. History of heart disease, glaucoma, peptic ulcer and aspirin-induced asthma 7. On medical treatment (exclude NSAIDs and sleeping pills taken as needed) 8. On medical treatment of phosphodiesterase 5 9. Systolic blood pressure <90 mmHg 10. Body weight <40 kg or >90 kg 11. Not appropriate to this study by other reasons

Design outcomes

Secondary

Measure	Time frame
Relation between co-administration and change of blood pressure, pulse rate, lipid parameter and side effects. Relation between ALDH2 genotype and change of blood pressure, pulse rate, lipid parameter and side effects.	—

Primary

Measure	Time frame
Relation between co-administration of atorvastatin and the change of flow-mediated dilation, oxidative stress and high-sensitivity CRP. Relation between aldehyde dehydrogenase 2 genotype and the change of flow-mediated dilation, oxidative stress and high-sensitivity CRP.	—

Countries

Japan

Contacts

Public ContactTatsuya Yoshihara

Faculty of Medical Sciences, Kyushu University Department of Clinical Pharmacology

tatsuya@clipharm.med.kyushu-u.ac.jp092-642-6082

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026